RT Journal Article
SR Electronic
A1 Vinall, Maria
T1 Results from the Long-Term Extension of the AIM Trial
JF MD Conference Express
YR 2006
FD SAGE Publications
VO 6
IS 3
SP 13
OP 13
DO 10.1177/155989770600600305
UL http://mdc.sagepub.com/content/6/3/13.1.abstract
AB The results from the 2-year AIM (ABA in Inadequate responders to MTX) trial indicated that RA patients refractory to treatment with MTX, demonstrate significant reduction in radiographic progression after treatment with Abatacept [Ann Rheum Dis 2005;64(Suppl III):56].